[DEBUG-WINDOW 처리영역 보기]
즐겨찾기  |  뉴스레터  |  오늘의 정보 회원가입   로그인
BRIC홈 한국을 빛내는 사람들
스폰서배너광고 안내  배너1
전체보기 추천논문 상위피인용논문 인터뷰 그이후 한빛사통계
조성호 (Seong H. Cho) 저자 이메일 보기
경희대학교 의과대학, University of South Florida
조회 219  인쇄하기 주소복사 트위터 공유 페이스북 공유 
Soy isoflavones reduce asthma exacerbation in asthmatics with high PAI-1 producing genotypes
열기 Authors and Affiliations


The 4G4G genotype of plasminogen activator inhibitor-1 (PAI-1) is associated with increased plasma PAI-1 levels and poor asthma control. Previous studies suggest that soy isoflavones may reduce PAI-1 levels.

We sought to investigate PAI-1 genotype-specific differences of the soy isoflavone response in asthma outcomes.

A PAI-1 functional polymorphism (rs1799768, 4G5G) was characterized in subjects with poorly controlled asthma enrolled in a randomized clinical trial of soy isoflavones (n=265). Genotype-specific treatment responses on asthma outcomes were compared between soy isoflavones versus placebo. Normal human bronchial epithelial cells (NHBE) were cultured with or without TGF-β1 and/or genistein, and PAI-1 levels were measured.

The 4G4G/4G5G genotype was associated with a higher risk for allergy-related worsened asthma symptoms and eczema at baseline compared to the 5G5G genotype. There was a significant interaction between the genotype and soy isoflavone intervention on oral corticosteroid use for asthma exacerbation (p=0.005). In a subgroup analysis, soy isoflavones significantly reduced the use of oral corticosteroids (number of events/person-year) by four-fold compared to the placebo in the 4G4G/4G5G genotype (0.2 vs 0.8, relative risk 0.28, p <0.001) but not in the 5G5G genotype. Soy isoflavones reduced plasma PAI-1 levels compared to the placebo. Genistein treatment reduced TGF-β1-induced PAI-1 production in NHBE.

This study demonstrates that soy isoflavone treatment provides a significant benefit in reducing the number of severe asthma exacerbations in asthmatic subjects with the high PAI-1 producing genotype. PAI-1 polymorphisms can be used as a genetic biomarker for soy isoflavone responsive subjects with asthma.

Key words: soy isoflavones, genistein, asthma, exacerbation, PAI-1, polymorphisms 

- 형식: Research article
- 게재일: 2019년 01월 (BRIC 등록일 2019-02-01)
- 연구진: 국내(교신)+국외 연구진태극기
- 분야: Immunology
RNF20/40 의존적 eEF1BδL 모노유비퀴틴화에 의한 열충격 유전자 전사 조절[Nucleic Acids Res.]
발표: 인선아 (KAIST)
일자: 2019년 2월 22일 (금) 오후 02시 (한국시간)
언어: 한국어
참석자 접수신청하기

  댓글 0
조성호 님 전체논문보기 >
김대우 (서울대학교 의과대학)
김동규 (한림대학교 의과대학)
관련분야 논문보기

Google (by Seong H. Cho)
Pubmed (by Seong H. Cho)
프리미엄 Bio일정 Bio일정 프리미엄 안내
2019 Korean Researchers’ Night in AACR 참가 신청 안내 (미국 애틀랜타)
2019 Korean Researchers’ Night in AACR 참가 신청 안내 (미국 애틀랜타)
사전접수: ~2019.02.20
날짜: 2019.03.31
장소: Atlanta Marriott Marquis
[BRIC Webinar]RNF20/40 의존적 eEF1BδL 모노유비퀴틴화에 의한 열충격 유전자 전사 조절-인선아 (KAIST)
2019 서경배과학재단 신진과학자 연구지원 프로그램 공고
한빛사 홈  |  한빛사FAQ  |  한빛사 문의 및 제안
 |  BRIC소개  |  이용안내  |  이용약관  |  개인정보처리방침  |  이메일무단수집거부
Copyright © BRIC. All rights reserved.  |  문의 member@ibric.org
트위터 트위터    페이스북 페이스북    RSS서비스 RSS
1550398728 0.29758500
1550398728 0.69345800
0.39587306976318 초 소요